Home NDC 51991-853 REPAGLINIDE
Product NDC 51991-853
11-digit product format 519910853
Labeler code 51991
Product ID 51991-853_d791eddc-7e75-42af-946b-5c67ddbad99e
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name REPAGLINIDE
Dosage form TABLET
Route ORAL
Labeler Breckenridge Pharmaceutical, Inc.
Application ANDA091517
Marketing category ANDA
Marketing start 2015-05-01
Marketing end 2022-04-30
Substance REPAGLINIDE
Active strength 1 mg/1
Pharmacologic classes Glinide [EPC],Potassium Channel Antagonists [MoA]
NDC exclude flag No
Listing certified through 0000-00-00
Current FDA listing Historical FDA.report record Observed NDC auxiliary status history# This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.
Historic NDC status page 1 of 1 · 24 matching rows.
View current auxiliary records. · View the auxiliary file history.
Captured / source date, Dataset, Scope table Captured / source date Dataset Scope Package NDC Snapshot Source SHA-256 2025-12-14 17:58 UTC · source 2025-12-05 excluded product product d630ba8d3edf…732f749b63fb…2025-12-14 17:58 UTC · source 2025-12-05 excluded package package 51991-853-01 d630ba8d3edf…732f749b63fb…2025-08-27 00:01 UTC · source 2025-08-26 excluded product product f5e01cc5f278…a2eaf40c39c3…2025-08-27 00:01 UTC · source 2025-08-26 excluded package package 51991-853-01 f5e01cc5f278…a2eaf40c39c3…2025-04-01 02:39 UTC · source 2025-03-31 excluded product product 2ef7874e63bc…57b86245f4fa…2025-04-01 02:39 UTC · source 2025-03-31 excluded package package 51991-853-01 2ef7874e63bc…57b86245f4fa…2025-03-28 20:22 UTC · source 2025-03-28 excluded product product a1b67e2a42f9…c4cf2c586c0d…2025-03-28 20:22 UTC · source 2025-03-28 excluded package package 51991-853-01 a1b67e2a42f9…c4cf2c586c0d…2025-03-22 03:12 UTC · source 2025-03-21 excluded product product cfe11265f3b6…090c488252e2…2025-03-22 03:12 UTC · source 2025-03-21 excluded package package 51991-853-01 cfe11265f3b6…090c488252e2…2025-03-10 12:48 UTC · source 2025-03-10 excluded product product cdf11ea48f46…ba0047e9e063…2025-03-10 12:48 UTC · source 2025-03-10 excluded package package 51991-853-01 cdf11ea48f46…ba0047e9e063…2025-02-02 03:52 UTC · source 2025-01-31 excluded product product 302b2466d912…e7b80fea0513…2025-02-02 03:52 UTC · source 2025-01-31 excluded package package 51991-853-01 302b2466d912…e7b80fea0513…2025-01-20 13:05 UTC · source 2025-01-20 excluded product product ed331223b511…672a5bd82f5f…2025-01-20 13:05 UTC · source 2025-01-20 excluded package package 51991-853-01 ed331223b511…672a5bd82f5f…2025-01-11 03:41 UTC · source 2025-01-10 excluded product product 0efc9e666f02…f202fb6c5f17…2025-01-11 03:41 UTC · source 2025-01-10 excluded package package 51991-853-01 0efc9e666f02…f202fb6c5f17…2024-11-09 02:27 UTC · source 2024-11-08 excluded product product ad56d346431e…cc804d4bbf1e…2024-11-09 02:27 UTC · source 2024-11-08 excluded package package 51991-853-01 ad56d346431e…cc804d4bbf1e…2024-10-04 04:10 UTC · source 2024-10-03 excluded product product 367a005e9d99…383a685ebd0f…2024-10-04 04:10 UTC · source 2024-10-03 excluded package package 51991-853-01 367a005e9d99…383a685ebd0f…2024-07-10 04:00 UTC · source 2024-07-09 excluded product product 557ba5c1ecfa…9c80585c8c6e…2024-07-10 04:00 UTC · source 2024-07-09 excluded package package 51991-853-01 557ba5c1ecfa…9c80585c8c6e…
Source provenance: Browse the complete Orange Book source catalog · source snapshot 1 .
Orange Book products# Current product rows page 1 of 1 · 3 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date A091517-001 REPAGLINIDE REPAGLINIDE 0.5MG TABLET / ORAL 2015-04-24 A091517-002 REPAGLINIDE REPAGLINIDE 1MG TABLET / ORAL 2015-04-24 A091517-003 REPAGLINIDE REPAGLINIDE 2MG TABLET / ORAL 2015-04-24
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 4 · 123 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-02-19 14:30 UTC 2026-02 A091517-001 REPAGLINIDE 0.5MG TABLET / ORAL 2015-04-24 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 A091517-002 REPAGLINIDE 1MG TABLET / ORAL 2015-04-24 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 A091517-003 REPAGLINIDE 2MG TABLET / ORAL 2015-04-24 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 A091517-001 REPAGLINIDE 0.5MG TABLET / ORAL 2015-04-24 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 A091517-002 REPAGLINIDE 1MG TABLET / ORAL 2015-04-24 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 A091517-003 REPAGLINIDE 2MG TABLET / ORAL 2015-04-24 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 A091517-001 REPAGLINIDE 0.5MG TABLET / ORAL 2015-04-24 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 A091517-002 REPAGLINIDE 1MG TABLET / ORAL 2015-04-24 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 A091517-003 REPAGLINIDE 2MG TABLET / ORAL 2015-04-24 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 A091517-001 REPAGLINIDE 0.5MG TABLET / ORAL 2015-04-24 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 A091517-002 REPAGLINIDE 1MG TABLET / ORAL 2015-04-24 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 A091517-003 REPAGLINIDE 2MG TABLET / ORAL 2015-04-24 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 A091517-001 REPAGLINIDE 0.5MG TABLET / ORAL 2015-04-24 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 A091517-002 REPAGLINIDE 1MG TABLET / ORAL 2015-04-24 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 A091517-003 REPAGLINIDE 2MG TABLET / ORAL 2015-04-24 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 A091517-001 REPAGLINIDE 0.5MG TABLET / ORAL 2015-04-24 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 A091517-002 REPAGLINIDE 1MG TABLET / ORAL 2015-04-24 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 A091517-003 REPAGLINIDE 2MG TABLET / ORAL 2015-04-24 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 A091517-001 REPAGLINIDE 0.5MG TABLET / ORAL 2015-04-24 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 A091517-002 REPAGLINIDE 1MG TABLET / ORAL 2015-04-24 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 A091517-003 REPAGLINIDE 2MG TABLET / ORAL 2015-04-24 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 A091517-001 REPAGLINIDE 0.5MG TABLET / ORAL 2015-04-24 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 A091517-002 REPAGLINIDE 1MG TABLET / ORAL 2015-04-24 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 A091517-003 REPAGLINIDE 2MG TABLET / ORAL 2015-04-24 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 A091517-001 REPAGLINIDE 0.5MG TABLET / ORAL 2015-04-24 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 A091517-002 REPAGLINIDE 1MG TABLET / ORAL 2015-04-24 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 A091517-003 REPAGLINIDE 2MG TABLET / ORAL 2015-04-24 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 A091517-001 REPAGLINIDE 0.5MG TABLET / ORAL 2015-04-24 d06236e962d9…2024-10-29 15:01 UTC 2024-10 A091517-002 REPAGLINIDE 1MG TABLET / ORAL 2015-04-24 d06236e962d9…2024-10-29 15:01 UTC 2024-10 A091517-003 REPAGLINIDE 2MG TABLET / ORAL 2015-04-24 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 A091517-001 REPAGLINIDE 0.5MG TABLET / ORAL 2015-04-24 79d66fd596c7…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 A091517-002 REPAGLINIDE 1MG TABLET / ORAL 2015-04-24 79d66fd596c7…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 A091517-003 REPAGLINIDE 2MG TABLET / ORAL 2015-04-24 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 A091517-001 REPAGLINIDE 0.5MG TABLET / ORAL 2015-04-24 301d65b070ca…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 A091517-002 REPAGLINIDE 1MG TABLET / ORAL 2015-04-24 301d65b070ca…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 A091517-003 REPAGLINIDE 2MG TABLET / ORAL 2015-04-24 301d65b070ca…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 A091517-001 REPAGLINIDE 0.5MG TABLET / ORAL 2015-04-24 1e350fbaab3a…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 A091517-002 REPAGLINIDE 1MG TABLET / ORAL 2015-04-24 1e350fbaab3a…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 A091517-003 REPAGLINIDE 2MG TABLET / ORAL 2015-04-24 1e350fbaab3a…2024-05-31 18:47 UTC 2024-05 A091517-001 REPAGLINIDE 0.5MG TABLET / ORAL 2015-04-24 8072bd15b7f6…
Observed Orange Book normalized TE history# Normalized TE history page 1 of 2 · 42 observed states.
DailyMed Socrata Ingredients# Ingredient, Type, UNII table Ingredient Type UNII DailyMed label SPL version Uploaded REPAGLINIDE ACTIVE INGREDIENT 668Z8C33LU REPAGLINIDE TABLET [BRECKENRIDGE PHARMACEUTICAL, INC.] 2 REPAGLINIDE ACTIVE MOIETY 668Z8C33LU REPAGLINIDE TABLET [BRECKENRIDGE PHARMACEUTICAL, INC.] 2 CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS INACTIVE INGREDIENT L11K75P92J REPAGLINIDE TABLET [BRECKENRIDGE PHARMACEUTICAL, INC.] 2 CELLULOSE, MICROCRYSTALLINE INACTIVE INGREDIENT OP1R32D61U REPAGLINIDE TABLET [BRECKENRIDGE PHARMACEUTICAL, INC.] 2 FERRIC OXIDE RED INACTIVE INGREDIENT 1K09F3G675 REPAGLINIDE TABLET [BRECKENRIDGE PHARMACEUTICAL, INC.] 2 FERRIC OXIDE YELLOW INACTIVE INGREDIENT EX438O2MRT REPAGLINIDE TABLET [BRECKENRIDGE PHARMACEUTICAL, INC.] 2 MAGNESIUM STEARATE INACTIVE INGREDIENT 70097M6I30 REPAGLINIDE TABLET [BRECKENRIDGE PHARMACEUTICAL, INC.] 2 POLACRILIN POTASSIUM INACTIVE INGREDIENT 0BZ5A00FQU REPAGLINIDE TABLET [BRECKENRIDGE PHARMACEUTICAL, INC.] 2 POLOXAMER 407 INACTIVE INGREDIENT TUF2IVW3M2 REPAGLINIDE TABLET [BRECKENRIDGE PHARMACEUTICAL, INC.] 2 POVIDONE K30 INACTIVE INGREDIENT U725QWY32X REPAGLINIDE TABLET [BRECKENRIDGE PHARMACEUTICAL, INC.] 2
Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Marketing start Marketing end Sample Exclude flag Status 51991-853-01 51991085301 100 TABLET in 1 BOTTLE (51991-853-01) 100 tablet 2015-05-01 2022-04-30 No No Current